


PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference PC25862A	FOR FURTHER ACTION		See Form PCT/PEA416
International application No. PCT/IB2005/000030	International filing date (day/month/year) 10.01.2005	Priority date (day/month/year) 20.01.2004	
International Patent Classification (IPC) or national classification and IPC A61K31/4164			
Applicant WARNER-LAMBERT COMPANY LLC et al.			
1.. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of 6 sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: a. <input type="checkbox"/> sent to the applicant and to the International Bureau a total of sheets, as follows: <input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box. b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).			
4. This report contains indications relating to the following items: <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> Box No. I Basis of the opinion <input type="checkbox"/> Box No. II Priority <input checked="" type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability <input type="checkbox"/> Box No. IV Lack of unity of invention <input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement <input type="checkbox"/> Box No. VI Certain documents cited <input type="checkbox"/> Box No. VII Certain defects in the international application <input type="checkbox"/> Box No. VIII Certain observations on the international application </div>			
Date of submission of the demand 17.02.2005		Date of completion of this report 13.12.2005	
Name and mailing address of the international preliminary examining authority: <div style="margin-left: 20px;"> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div>		Authorized Officer Seymour, L Telephone No. +49 89 2399-	



**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/IB2005/000030

Box No. I Basis of the report

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
- ☐ This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3 and 23.1(b))
 - ☐ publication of the international application (under Rule 12.4)
 - ☐ international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements*** of the international application, this report is based on *(replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):*

Description, Pages

1-97 as originally filed

Claims, Numbers

1-15 as originally filed

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3. ☐ The amendments have resulted in the cancellation of:
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):
4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
- ☐ the description, pages
 - ☐ the claims, Nos.
 - ☐ the drawings, sheets/figs
 - ☐ the sequence listing (*specify*):
 - ☐ any table(s) related to sequence listing (*specify*):

* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/IB2005/000030

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 1-15 with respect to prodrugs

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. as above

☐ the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form

☐ has not been furnished

☐ does not comply with the standard

the computer readable form

☐ has not been furnished

☐ does not comply with the standard

☐ the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-*bis* of the Administrative Instructions.

☐ See separate sheet for further details

**INTERNATIONAL PRELIMINARY REPORT
ON PATENTABILITY**

International application No.
PCT/IB2005/000030

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	3,4,6-8
	No: Claims	1,2,5,9-15
Inventive step (IS)	Yes: Claims	
	No: Claims	1-15
Industrial applicability (IA)	Yes: Claims	1-15
	No: Claims	

2. Citations and explanations (Rule 70.7):

see separate sheet

**INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(SEPARATE SHEET)**

International application No.

PCT/IB2005/000030

Re Item III

The present claims do not fulfil the requirements of Articles 5 and 6 PCT to such an extent as to render a meaningful search impossible. It is unclear which technical features are necessary to perform the functional term "prodrug" and thus which specific compounds fall within the scope of the present claims. Moreover, this functional definition is a mere invitation to the skilled person to perform a research program in order to find the suitable variants (cf. definition in description p. 16). The invention cannot be carried out over the whole claimed area without imposing an undue burden on the skilled person, and the disclosure is thus considered to be insufficient. Consequently, the search and examination do not include prodrugs of the claimed compounds.

Re Item V

1. Reference is made to the following documents:
D1: US-A-4 808 607 D2: USA-4 968 681 D3: EP-A-0 300 278
2. The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1, 2, 5 and 9-15 is not new in the sense of Article 33(2) PCT: The subject-matter of said claims overlaps with the disclosure of D1 and specific embodiments of D1 fall within the area of overlap (see passages referred to in search report).

The compounds of D2 differ from the present compounds in that they are hydroxylamines.

The compounds of D3 differ from the present compounds in that they are pyrrole derivatives.

3. The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of the present claims does not involve an inventive step in the sense of Article 33(3) PCT.

The problem underlying the present application is seen in the provision of further imidazole derivatives as HMG-CoA reductase inhibitors and inhibitors of cholesterol biosynthesis (cf. present description, p. 4, lines 2-6).

**INTERNATIONAL PRELIMINARY
REPORT ON PATENTABILITY
(SEPARATE SHEET)**

International application No.

PCT/IB2005/000030

Document D1, which is regarded as being the closest prior art, discloses imidazole derivatives having the present activity and structure. The types of substituents R^2 claimed in novel claims 3, 4 and 6-8 have been suggested in D2 and D3 for other closely related HMG-CoA reductase inhibitors containing C-linked imidazole and pyrrole templates: D2, column 1, line 14 - column 3, line 6, particularly definition of C^1 ; D3, p. 6, l. 43 - p. 8, l. 4, particularly formula Ia, definition of R^4 . It would therefore have been obvious for the person skilled in the art, faced with the above-mentioned problem, to modify the known compounds as claimed.

An inventive step cannot therefore be acknowledged, in the absence of evidence showing that substantially all the claimed compounds have an unexpected property or improved activity with respect to the structurally closest prior art compounds, attributable to the distinguishing feature of the invention, which has yet to be established.